Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEK1
- Development stage
- Preclinical
- Lead developer
- Turbine
- Modality
- Small Molecules
01
Overview
NEK1 refers to a novel cancer therapy being co-developed by Turbine and Harmonic Discovery. This therapy is a kinase inhibitor designed to target the NIMA-related kinase 1 (NEK1), which has been identified as a 'dark kinase' and a cancer-driving target. Turbine utilizes its Simulated Cell™ platform for target identification and validation, including identifying synergistic co-targets and patient populations. Harmonic Discovery employs its generative chemistry platform for the design and development of these kinase inhibitors. The collaboration aims to create differentiated kinase inhibitor therapies for cancer.
02
Targets
NEK1 (NIMA related kinase 1)
Beyond the preview
Go deeper on NEK1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEK1.